Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02485834 · ClinicalTrials.gov registry record · Phase 2
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02485834 is a Phase 2 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 5 participants.
The verdict
NCT02485834, a Phase 2 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread past the stomach and is not responding to the usual treatment. PET scans are a different way to take pictures of cancer and can be used to look at how much energy (such as glucose) is being used by the cancer. Using PET scans early to monitor the success of treatment may allow doctors to measure response and change treatment accordingly.
Interventions
- DRUG 5-FU
- DRUG docetaxel
- DRUG capecitabine
- PROCEDURE surgery
- PROCEDURE FDG-PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-11-12 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02485834
The ClinicalTrials.gov registry entry for NCT02485834 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 5-FU is the first listed.
NCT02485834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02485834 about?
NCT02485834 is a clinical study titled "FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer". This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread past the stomach and is not responding to the usual treatment. PET scans...
What is the current status of trial NCT02485834?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-11-12. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT02485834?
The interventions under investigation include: 5-FU (DRUG), docetaxel (DRUG), capecitabine (DRUG), surgery (PROCEDURE), FDG-PET (PROCEDURE).
Who is sponsoring clinical trial NCT02485834?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.